NCT05575804

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2022-10-01Est. Completion: 2028-12-31

Enrollment target: 32 participants

Locations

Contact

Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination wi…

Birmingham, United StatesEst. completion Dec 30, 2027

Invasive Breast Cancer

This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis o…

Milwaukee, United StatesEst. completion Aug 11, 2025

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.